LUCD - Lucid Diagnostics gains as analyst sees over 200% upside

Medical diagnostics company Lucid Diagnostics (NASDAQ:LUCD) has added ~8.9% in the pre-market on below-average volume after Ascendiant Capital began its coverage on the micro-cap stock with a $16 per share target to imply a premium of ~225.2% upside to Thursday’s close. About 56.2K Lucid (LUCD) shares have changed hands so far, compared to the 65-day average volume of ~344.8K. With a Buy rating on the stock, the analyst Edward Woo argues that the New York-based company has “large” market potential. While the company still faces challenges in commercializing its devices, there will be high rewards for the risks given the billion-dollar market opportunity, according to Woo. A subsidiary of PAVmed (NASDAQ:PAVM), Lucid (LUCD) made its public debut in October. However, the stock has lost more than a third over the past 30 days. Recently, in a Bullish thesis on PAVmed (PAVM), Seeking Alpha contributor Shareholders Unite argued that the stock “has much

For further details see:

Lucid Diagnostics gains as analyst sees over 200% upside